News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arginetix Completes $2.3M Initial Round



10/23/2008 8:38:59 AM

BALTIMORE--(BUSINESS WIRE)--Arginetix, Inc., a biopharmaceutical company dedicated to developing and commercializing novel therapeutic small molecule inhibitors of arginase, announced today that it has completed a $2.3 million initial financing. The financing was co-led by Quaker BioVentures and MedImmune Ventures. Other investors included Red Abbey Venture Partners, Maryland Health Care Product Development Corporation and Acidophil LLC. The company’s scientific foundation is based on discoveries of the scientific co-founders, David Christianson, Ph.D. at the University of Pennsylvania and Dan Berkowitz M.D. at the Johns Hopkins University.

Read at Business Wire


comments powered by Disqus
Arginetix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES